Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax
Evan C. Chen(Dana-Farber Cancer Institute), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan)), Kevin Copson(Dana-Farber Cancer Institute), Eric S. Winer(Providence College), Marlise R. Luskin(Dana-Farber Cancer Institute), Rahul S. Vedula(Harvard University), Coleman Lindsley, Martha Wadleigh(Dana-Farber Cancer Institute), Andrew A. Lane(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Yiwen Liu(University of Arizona), Anne Charles(Dana-Farber Cancer Institute), Nicolas C. Issa(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k